Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
GSK exclusive license agreement with Empirico
We advised GSK on the transaction
ADC Therapeutics $60 million private placement
We advised ADC Therapeutics on the transaction involving its common shares and pre-funded warrants
Aveanna $90 million secondary offering
The shares are listed on the Nasdaq Global Select Market
RAPT Therapeutics $250 million follow-on offering
The shares are listed on the Nasdaq Global Market
Nurix Therapeutics $250 million stock offering
The stock is listed on the Nasdaq Global Market
Blackstone and TPG $12.25 billion Hologic acquisition financing
We are advising the lead arrangers and bookrunners on the financing
GRAIL $325 million private placement
The PIPE included common stock and pre-funded warrants
Pharmaceutical company $550 million preferred equity acquisition financing
We advised the preferred equity financing sources on the transaction
Esperion Therapeutics follow-on offering
The shares are listed on Nasdaq
Turn Therapeutics direct listing
We advised Turn Therapeutics on its Nasdaq listing